MORF vs. KURA, AKRO, DAWN, EWTX, RCUS, ANIP, ARDX, ZLAB, GYRE, and DVAX
Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Kura Oncology (KURA), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Ardelyx (ARDX), Zai Lab (ZLAB), Gyre Therapeutics (GYRE), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.
Morphic (NASDAQ:MORF) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
94.3% of Morphic shares are owned by institutional investors. 28.1% of Morphic shares are owned by insiders. Comparatively, 5.5% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Kura Oncology received 320 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 68.74% of users gave Kura Oncology an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Morphic has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Morphic, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kura Oncology had 6 more articles in the media than Morphic. MarketBeat recorded 13 mentions for Kura Oncology and 7 mentions for Morphic. Morphic's average media sentiment score of 1.15 beat Kura Oncology's score of 0.59 indicating that Morphic is being referred to more favorably in the media.
Morphic has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Morphic's return on equity of -22.50% beat Kura Oncology's return on equity.
Morphic currently has a consensus price target of $51.50, suggesting a potential upside of 83.47%. Kura Oncology has a consensus price target of $28.28, suggesting a potential upside of 43.91%. Given Morphic's higher probable upside, equities research analysts clearly believe Morphic is more favorable than Kura Oncology.
Summary
Morphic beats Kura Oncology on 10 of the 16 factors compared between the two stocks.
Get Morphic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
